| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T98459 | ||||
| Target Name | G2/mitotic-specific cyclin B1 | ||||
| Target Type | Research |
||||
| Drug Potency against Target | Thieno analogue of kenpaullone | Drug Info | IC50 = 600 nM | [1] | |
| 3,4-bis(indol-3-yl)maleimide derivative | Drug Info | IC50 = 4500 nM | [2] | ||
| AZAKENPAULLONE | Drug Info | IC50 = 2000 nM | [1] | ||
| KENPAULLONE | Drug Info | IC50 = 400 nM | [3] | ||
| GF-109203 | Drug Info | IC50 = 19000 nM | [2] | ||
| RO-316233 | Drug Info | IC50 = 18000 nM | [2] | ||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. | ||||
| REF 2 | Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. | ||||
| REF 3 | Eur J Med Chem. 2010 Sep;45(9):4316-30. Epub 2010 Jun 30.Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.